Metoclopramide Side Effects
Brand Names: Reglan
Please note - some side effects for Metoclopramide may not be reported. Always consult your doctor or healthcare specialist for medical advice. You may also report side effects to the FDA at http://www.fda.gov/medwatch/ or 1-800-FDA-1088 (1-800-332-1088).
|
For the consumer For the professional
|
|
Side Effects of Metoclopramide - for the consumer
Metoclopramide
All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome when using Metoclopramide:
Seek medical attention right away if any of these SEVERE side effects occur when using Metoclopramide:Decreased energy; diarrhea; dizziness; drowsiness; headache; nausea; restlessness; tiredness; trouble sleeping.
Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue; unusual hoarseness); abnormal thinking; confusion; dark urine; decreased coordination; decreased sexual ability; fast, slow, or irregular heartbeat; fever; hallucinations; loss of bladder control; mental or mood changes (eg, depression, anxiety, agitation, jitteriness); seizures; severe or persistent dizziness, headache, or trouble sleeping; severe or persistent restlessness, including inability to sit still; shortness of breath; stiff or rigid muscles; sudden increased sweating; sudden unusual weight gain; suicidal thoughts or actions; swelling of the arms, legs, or feet; uncontrolled muscle movements (eg, of the arms, legs, tongue, jaw, cheeks; twitching; tremors); vision changes; yellowing of the skin or eyes.
Metoclopramide Solution
All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome when using Metoclopramide Solution:
Seek medical attention right away if any of these SEVERE side effects occur when using Metoclopramide Solution:Decreased energy; diarrhea; dizziness; drowsiness; headache; nausea; restlessness; tiredness; trouble sleeping.
Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue; unusual hoarseness); abnormal thinking; confusion; dark urine; decreased coordination; decreased sexual ability; fast, slow, or irregular heartbeat; fever; hallucinations; loss of bladder control; mental or mood changes (eg, depression, anxiety, agitation, jitteriness); seizures; severe or persistent dizziness, headache, or trouble sleeping; severe or persistent restlessness, including inability to sit still; shortness of breath; stiff or rigid muscles; sudden increased sweating; sudden unusual weight gain; suicidal thoughts or actions; swelling of the arms, legs, or feet; uncontrolled muscle movements (eg, of the arms, legs, tongue, jaw, cheeks; twitching; tremors); vision changes; yellowing of the skin or eyes.
Metoclopramide Syrup
All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome when using Metoclopramide Syrup:
Seek medical attention right away if any of these SEVERE side effects occur when using Metoclopramide Syrup:Decreased energy; diarrhea; dizziness; drowsiness; headache; nausea; restlessness; tiredness; trouble sleeping.
TopSevere allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue; unusual hoarseness); abnormal thinking; confusion; dark urine; decreased coordination; decreased sexual ability; fast, slow, or irregular heartbeat; fever; hallucinations; loss of bladder control; mental or mood changes (eg, depression, anxiety, agitation, jitteriness); seizures; severe or persistent dizziness, headache, or trouble sleeping; severe or persistent restlessness, including inability to sit still; shortness of breath; stiff or rigid muscles; sudden increased sweating; sudden unusual weight gain; suicidal thoughts or actions; swelling of the arms, legs, or feet; uncontrolled muscle movements (eg, of the arms, legs, tongue, jaw, cheeks; twitching; tremors); vision changes; yellowing of the skin or eyes.
For the professional
Metoclopramide Injection
In general, the incidence of adverse reactions correlates with the dose and duration of Metoclopramide administration. The following reactions have been reported, although in most instances, data do not permit an estimate of frequency.
CNS Effects. Restlessness, drowsiness, fatigue and lassitude may occur in patients receiving the recommended prescribed dose of Metoclopramide. Insomnia, headache, confusion, dizziness and mental depression with suicidal ideation also may occur. In cancer chemotherapy patients being treated with 1-2 mg/kg per dose, incidence of drowsiness is about 70%. There are isolated reports of convulsive seizures without a clear-cut relationship to Metoclopramide. Rarely, hallucinations have been reported.
Extrapyramidal Reactions (EPS). Acute dystonic reactions, the most common type of EPS associated with Metoclopramide, occur in approximately 0.2% of patients (1 in 500) treated with 30 to 40 mg of Metoclopramide per day. In cancer chemotherapy patients receiving 1-2 mg/kg per dose, the incidence is 2% in patients over the ages of 30-35, and 25% or higher in pediatric patients and adult patients less than 30 years of age who have not had prophylactic administration of diphenhydramine. Symptoms include involuntary movements of limbs, facial grimacing, torticollis, oculogyric crisis, rhythmic protrusion of tongue, bulbar type of speech, trismus, opisthotonus (tetanus-like reactions) and rarely, stridor and dyspnea, possibly due to laryngospasm; ordinarily these symptoms are readily reversed by diphenhydramine.
Parkinsonian-like symptoms may include bradykinesia, tremor, cogwheel rigidity, mask-like facies.
Tardive dyskinesia most frequently is characterized by involuntary movements of the tongue, face, mouth or jaw, and sometimes by involuntary movements of the trunk and/or extremities; movements may be choreoathetotic in appearance.
Motor restlessness (akathisia) may consist of feelings of anxiety, agitation, jitteriness, and insomnia, as well as inability to sit still, pacing, and foot tapping. These symptoms may disappear spontaneously or respond to a reduction in dosage.
Neuroleptic Malignant Syndrome. Rare occurrences of neuroleptic malignant syndrome (NMS) have been reported. This potentially fatal syndrome is comprised of the symptom complex of hyperthermia, muscular rigidity, altered consciousness, and autonomic instability.
Endocrine Disturbances. Galactorrhea, amenorrhea, gynecomastia, impotence secondary to hyperprolactinemia. Fluid retention secondary to transient elevation of aldosterone.
Cardiovascular. Hypotension, hypertension, supraventricular tachycardia, bradycardia, fluid retention, acute congestive heart failure, and possible atrioventricular (AV) block.
Gastrointestinal. Nausea and bowel disturbances, primarily diarrhea.
Hepatic. Rarely, cases of hepatotoxicity, characterized by such findings as jaundice and altered liver function tests, when Metoclopramide was administered with other drugs with known hepatotoxic potential.
Renal. Urinary frequency and incontinence.
Hematologic. A few cases of neutropenia, leukopenia, or agranulocytosis, generally without a clear-cut relationship to Metoclopramide. Methemoglobinemia, in adults and especially with overdosage in neonates. Sulfhemoglobinemia in adults.
Allergic Reactions. A few cases of rash, urticaria, or bronchospasm, especially in patients with a history of asthma. Rarely, angioneurotic edema, including glossal or laryngeal edema.
Miscellaneous. Visual disturbances, Porphyria.
Transient flushing of the face and upper body, without alterations in vital signs, following high doses intravenously.
TopMetoclopramide Injection USP
In general, the incidence of adverse reactions correlates with the dose and duration of Metoclopramide administration. The following reactions have been reported, although in most instances, data do not permit an estimate of frequency.
CNS Effects: Restlessness, drowsiness, fatigue and lassitude may occur in patients receiving the recommended prescribed dose of Metoclopramide injection. Insomnia, headache, confusion, dizziness or mental depression with suicidal ideation also may occur . In cancer chemotherapy patients being treated with 1-2 mg/kg per dose incidence of drowsiness is about 70%. There are isolated reports of convulsive seizures without a clear-cut relationship to Metoclopramide. Rarely, hallucinations have been reported.
Extrapyramidal Reactions (EPS): Acute dystonic reactions, the most common type of EPS associated with Metoclopramide, occur in approximately 0.2% of patients (1 in 500) treated with 30 mg to 40 mg of Metoclopramide per day. In cancer chemotherapy patients receiving 1-2 mg/kg per dose, the incidence is 2% in patients over the ages of 30-35, and 25% or higher in pediatric patients and adult patients less than 30 years of age who have not had prophylactic administration of diphenhydramine. Symptoms include involuntary movements of limbs, facial grimacing, torticollis, oculogyric crisis, rhythmic protrusion of tongue, bulbar type of speech, trismus, opisthotonus (tetanus-like reactions) and rarely, stridor and dyspnea possibly due to laryngospasm; ordinarily these symptoms are readily reversed by diphenhydramine.
Parkinsonian-like symptoms may include bradykinesia, tremor, cogwheel rigidity, mask-like facies.
Tardive dyskinesia most frequently is characterized by involuntary movements of the tongue, face, mouth or jaw, and sometimes by involuntary movements of the trunk and/or extremities; movements may be choreoathetotic in appearance.
Motor restlessness (akathisia) may consist of feelings of anxiety, agitation, jitteriness, and insomnia, as well as inability to sit still, pacing, foot-tapping. These symptoms may disappear spontaneously or respond to a reduction in dosage.
Neuroleptic Malignant Syndrome: Rare occurrences of neuroleptic malignant syndrome (NMS) have been reported. This potentially fatal syndrome is comprised of the symptom complex of hyperthermia, muscular rigidity, altered consciousness, and autonomic instability .
Endocrine Disturbances: Galactorrhea, amenorrhea, gynecomastia, impotence secondary to hyperprolactinemia . Fluid retention secondary to transient elevation of aldosterone.
Cardiovascular: Hypotension, hypertension, supraventricular tachycardia, bradycardia, fluid retention, acute congestive heart failure, and possible atrioventricular (AV) block .
Gastrointestinal: Nausea and bowel disturbances, primarily diarrhea.
Hepatic: Rarely, cases of hepatotoxicity, characterized by such findings as jaundice and altered liver function tests, when Metoclopramide was administered with other drugs with known hepatotoxic potential.
Renal: Urinary frequency and incontinence.
Hematologic: A few cases of neutropenia, leukopenia, or agranulocytosis, generally without a clear-cut relationship to Metoclopramide. Methemoglobinemia in adults and especially with overdosage in neonates. Sulfhemoglobinemia in adults.
Allergic Reactions: A few cases of rash, urticaria, or bronchospasm, especially in patients with a history of asthma. Rarely, angioneurotic edema, including glossal or laryngeal edema.
Miscellaneous: Visual disturbances. Porphyria. Transient flushing of the face and upper body, without alterations in vital signs, following high doses intravenously.
TopMetoclopramide Injection USP
In general, the incidence of adverse reactions correlates with the dose and duration of Metoclopramide administration. The following reactions have been reported, although in most instances, data do not permit an estimate of frequency.
CNS Effects: Restlessness, drowsiness, fatigue and lassitude may occur in patients receiving the recommended prescribed dose of Metoclopramide injection. Insomnia, headache, confusion, dizziness or mental depression with suicidal ideation also may occur . In cancer chemotherapy patients being treated with 1-2 mg/kg per dose incidence of drowsiness is about 70%. There are isolated reports of convulsive seizures without a clear-cut relationship to Metoclopramide. Rarely, hallucinations have been reported.
Extrapyramidal Reactions (EPS): Acute dystonic reactions, the most common type of EPS associated with Metoclopramide, occur in approximately 0.2% of patients (1 in 500) treated with 30 mg to 40 mg of Metoclopramide per day. In cancer chemotherapy patients receiving 1-2 mg/kg per dose, the incidence is 2% in patients over the ages of 30-35, and 25% or higher in pediatric patients and adult patients less than 30 years of age who have not had prophylactic administration of diphenhydramine. Symptoms include involuntary movements of limbs, facial grimacing, torticollis, oculogyric crisis, rhythmic protrusion of tongue, bulbar type of speech, trismus, opisthotonus (tetanus-like reactions) and rarely, stridor and dyspnea possibly due to laryngospasm; ordinarily these symptoms are readily reversed by diphenhydramine.
Parkinsonian-like symptoms may include bradykinesia, tremor, cogwheel rigidity, mask-like facies.
Tardive dyskinesia most frequently is characterized by involuntary movements of the tongue, face, mouth or jaw, and sometimes by involuntary movements of the trunk and/or extremities; movements may be choreoathetotic in appearance.
Motor restlessness (akathisia) may consist of feelings of anxiety, agitation, jitteriness, and insomnia, as well as inability to sit still, pacing, foot-tapping. These symptoms may disappear spontaneously or respond to a reduction in dosage.
Neuroleptic Malignant Syndrome: Rare occurrences of neuroleptic malignant syndrome (NMS) have been reported. This potentially fatal syndrome is comprised of the symptom complex of hyperthermia, muscular rigidity, altered consciousness, and autonomic instability .
Endocrine Disturbances: Galactorrhea, amenorrhea, gynecomastia, impotence secondary to hyperprolactinemia . Fluid retention secondary to transient elevation of aldosterone.
Cardiovascular: Hypotension, hypertension, supraventricular tachycardia, bradycardia, fluid retention, acute congestive heart failure, and possible atrioventricular (AV) block .
Gastrointestinal: Nausea and bowel disturbances, primarily diarrhea.
Hepatic: Rarely, cases of hepatotoxicity, characterized by such findings as jaundice and altered liver function tests, when Metoclopramide was administered with other drugs with known hepatotoxic potential.
Renal: Urinary frequency and incontinence.
Hematologic: A few cases of neutropenia, leukopenia, or agranulocytosis, generally without a clear-cut relationship to Metoclopramide. Methemoglobinemia in adults and especially with overdosage in neonates. Sulfhemoglobinemia in adults.
Allergic Reactions: A few cases of rash, urticaria, or bronchospasm, especially in patients with a history of asthma. Rarely, angioneurotic edema, including glossal or laryngeal edema.
Miscellaneous: Visual disturbances. Porphyria. Transient flushing of the face and upper body, without alterations in vital signs, following high doses intravenously.
TopMetoclopramide Oral Solution
In general, the incidence of adverse reactions correlates with the dose and duration of Metoclopramide administration. The following reactions have been reported, although in most instances, data do not permit an estimate of frequency:
CNS Effects
Restlessness, drowsiness, fatigue, and lassitude occur in approximately 10% of patients receiving the most commonly prescribed dosage of 10 mg q.i.d.. Insomnia, headache, confusion, dizziness, or mental depression with suicidal ideation occur less frequently. There are isolated reports of convulsive seizures without clearcut relationship to Metoclopramide. Rarely, hallucinations have been reported.
Extrapyramidal Reactions (EPS)
Acute dystonic reactions, the most common type of EPS associated with Metoclopramide, occur in approximately 0.2% of patients (1 in 500) treated with 30 to 40 mg of Metoclopramide per day. Symptoms include involuntary movements of limbs, facial grimacing, torticollis, oculogyric crisis, rhythmic protrusion of tongue, bulbar type of speech, trismus, opisthotonus (tetanus-like reactions), and, rarely, stridor and dyspnea possibly due to laryngospasm; ordinarily these symptoms are readily reversed by diphenhydramine.
Parkinsonian-like symptoms may include bradykinesia, tremor, cogwheel rigidity, mask-like facies.
Tardive dyskinesia most frequently is characterized by involuntary movements of the tongue, face, mouth, or jaw, and sometimes by involuntary movements of the trunk and/or extremities; movements may be choreoathetotic in appearance.
Motor restlessness (akathisia) may consist of feelings of anxiety, agitation, jitteriness, and insomnia, as well as inability to sit still, pacing, foot tapping. These symptoms may disappear spontaneously or respond to a reduction in dosage.
Endocrine Disturbances
Galactorrhea, amenorrhea, gynecomastia, impotence secondary to hyperprolactinemia. Fluid retention secondary to transient elevation of aldosterone.
Cardiovascular
Hypotension, hypertension, supraventricular tachycardia, bradycardia, fluid retention, acute congestive heart failure, and possible AV block.
Gastrointestinal
Nausea and bowel disturbances, primarily diarrhea.
Hepatic
Rarely, cases of hepatotoxicity, characterized by such findings as jaundice and altered liver function tests, when Metoclopramide was administered with other drugs with known hepatotoxic potential.
Renal
Urinary frequency and incontinence.
Hematologic
A few cases of neutropenia, leukopenia, or agranulocytosis, generally without clearcut relationship to Metoclopramide. Methemoglobinemia, especially with overdosage in neonates.
Sulfhemoglobinemia in adults.
Allergic Reactions
A few cases of rash, urticaria, or bronchospasm, especially in patients with a history of asthma. Rarely, angioneurotic edema, including glossal or laryngeal edema.
Miscellaneous
Visual disturbances. Porphyria. Rare occurrences of neuroleptic malignant syndrome (NMS) have been reported. This potentially fatal syndrome is comprised of the symptom complex of hyperthermia, altered consciousness, muscular rigidity, and autonomic dysfunction.
TopMetoclopramide Tablets
In general, the incidence of adverse reactions correlates with the dose and duration of Metoclopramide administration. The following reactions have been reported, although in most instances, data do not permit an estimate of frequency:
CNS Effects
Restlessness, drowsiness, fatigue, and lassitude occur in approximately 10% of patients receiving the most commonly prescribed dosage of 10 mg q.i.d.. Insomnia, headache, confusion, dizziness, or mental depression with suicidal ideation occur less frequently. The incidence of drowsiness is greater at higher doses. There are isolated reports of convulsive seizures without clearcut relationship to Metoclopramide. Rarely, hallucinations have been reported.
Extrapyramidal Reactions (EPS)
Acute dystonic reactions, the most common type of EPS associated with Metoclopramide, occur in approximately 0.2% of patients (1 in 500) treated with 30 to 40 mg of Metoclopramide per day. Symptoms include involuntary movements of limbs, facial grimacing, torticollis, oculogyric crisis, rhythmic protrusion of tongue, bulbar type of speech, trismus, opisthotonus (tetanus-like reactions), and, rarely, stridor and dyspnea possibly due to laryngospasm; ordinarily these symptoms are readily reversed by diphenhydramine.
Parkinsonian-like symptoms may include bradykinesia, tremor, cogwheel rigidity, mask-like facies.
Tardive dyskinesia most frequently is characterized by involuntary movements of the tongue, face, mouth, or jaw, and sometimes by involuntary movements of the trunk and/or extremities; movements may be choreoathetotic in appearance.
Motor restlessness (akathisia) may consist of feelings of anxiety, agitation, jitteriness, and insomnia, as well as inability to sit still, pacing, foot tapping. These symptoms may disappear spontaneously or respond to a reduction in dosage.
Neuroleptic Malignant Syndrome
Rare occurrences of neuroleptic malignant syndrome (NMS) have been reported. This potentially fatal syndrome is comprised of the symptom complex of hyperthermia, altered consciousness, muscular rigidity, and autonomic dysfunction.
Endocrine Disturbances
Galactorrhea, amenorrhea, gynecomastia, impotence secondary to hyperprolactinemia. Fluid retention secondary to transient elevation of aldosterone.
Cardiovascular
Hypotension, hypertension, supraventricular tachycardia, bradycardia, fluid retention, acute congestive heart failure and possible AV block.
Gastrointestinal
Nausea and bowel disturbances, primarily diarrhea.
Hepatic
Rarely, cases of hepatotoxicity, characterized by such findings as jaundice and altered liver function tests, when Metoclopramide was administered with other drugs with known hepatotoxic potential.
Renal
Urinary frequency and incontinence.
Hematologic
A few cases of neutropenia, leukopenia, or agranulocytosis, generally without clearcut relationship to Metoclopramide. Methemoglobinemia, in adults and especially with overdosage in neonates. Sulfhemoglobinemia in adults.
Allergic Reactions
A few cases of rash, urticaria, or bronchospasm, especially in patients with a history of asthma. Rarely, angioneurotic edema, including glossal or laryngeal edema.
Miscellaneous
Visual disturbances. Porphyria.
TopMore resources:
Metoclopramide - Includes detailed dosage instructions.
Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This information does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug of drug combination is safe, effective, or appropriate for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of information provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.
